192 related articles for article (PubMed ID: 31378982)
1. Ammonia Scavenging Prevents Progression of Fibrosis in Experimental Nonalcoholic Fatty Liver Disease.
De Chiara F; Thomsen KL; Habtesion A; Jones H; Davies N; Gracia-Sancho J; Manicardi N; Hall A; Andreola F; Paish HL; Reed LH; Watson AA; Leslie J; Oakley F; Rombouts K; Mookerjee RP; Mann J; Jalan R
Hepatology; 2020 Mar; 71(3):874-892. PubMed ID: 31378982
[TBL] [Abstract][Full Text] [Related]
2. Urea cycle dysregulation in non-alcoholic fatty liver disease.
De Chiara F; Heebøll S; Marrone G; Montoliu C; Hamilton-Dutoit S; Ferrandez A; Andreola F; Rombouts K; Grønbæk H; Felipo V; Gracia-Sancho J; Mookerjee RP; Vilstrup H; Jalan R; Thomsen KL
J Hepatol; 2018 Oct; 69(4):905-915. PubMed ID: 29981428
[TBL] [Abstract][Full Text] [Related]
3. Ammonia: A novel target for the treatment of non-alcoholic steatohepatitis.
Thomsen KL; De Chiara F; Rombouts K; Vilstrup H; Andreola F; Mookerjee RP; Jalan R
Med Hypotheses; 2018 Apr; 113():91-97. PubMed ID: 29523305
[TBL] [Abstract][Full Text] [Related]
4. Fatty Acids Activate the Transcriptional Coactivator YAP1 to Promote Liver Fibrosis via p38 Mitogen-Activated Protein Kinase.
Salloum S; Jeyarajan AJ; Kruger AJ; Holmes JA; Shao T; Sojoodi M; Kim MH; Zhuo Z; Shroff SG; Kassa A; Corey KE; Khan SK; Lin W; Alatrakchi N; Schaefer EAK; Chung RT
Cell Mol Gastroenterol Hepatol; 2021; 12(4):1297-1310. PubMed ID: 34118488
[TBL] [Abstract][Full Text] [Related]
5. Steatosis induced CCL5 contributes to early-stage liver fibrosis in nonalcoholic fatty liver disease progress.
Li BH; He FP; Yang X; Chen YW; Fan JG
Transl Res; 2017 Feb; 180():103-117.e4. PubMed ID: 27639593
[TBL] [Abstract][Full Text] [Related]
6. Enhanced expression of BMP6 inhibits hepatic fibrosis in non-alcoholic fatty liver disease.
Arndt S; Wacker E; Dorn C; Koch A; Saugspier M; Thasler WE; Hartmann A; Bosserhoff AK; Hellerbrand C
Gut; 2015 Jun; 64(6):973-81. PubMed ID: 25011936
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of EGFR attenuates fibrosis and stellate cell activation in diet-induced model of nonalcoholic fatty liver disease.
Liang D; Chen H; Zhao L; Zhang W; Hu J; Liu Z; Zhong P; Wang W; Wang J; Liang G
Biochim Biophys Acta Mol Basis Dis; 2018 Jan; 1864(1):133-142. PubMed ID: 29038049
[TBL] [Abstract][Full Text] [Related]
8. Hepatocyte Hypoxia Inducible Factor-1 Mediates the Development of Liver Fibrosis in a Mouse Model of Nonalcoholic Fatty Liver Disease.
Mesarwi OA; Shin MK; Bevans-Fonti S; Schlesinger C; Shaw J; Polotsky VY
PLoS One; 2016; 11(12):e0168572. PubMed ID: 28030556
[TBL] [Abstract][Full Text] [Related]
9. Progression of non-alcoholic steatosis to steatohepatitis and fibrosis parallels cumulative accumulation of danger signals that promote inflammation and liver tumors in a high fat-cholesterol-sugar diet model in mice.
Ganz M; Bukong TN; Csak T; Saha B; Park JK; Ambade A; Kodys K; Szabo G
J Transl Med; 2015 Jun; 13():193. PubMed ID: 26077675
[TBL] [Abstract][Full Text] [Related]
10. Activation of Insulin-PI3K/Akt-p70S6K Pathway in Hepatic Stellate Cells Contributes to Fibrosis in Nonalcoholic Steatohepatitis.
Cai CX; Buddha H; Castelino-Prabhu S; Zhang Z; Britton RS; Bacon BR; Neuschwander-Tetri BA
Dig Dis Sci; 2017 Apr; 62(4):968-978. PubMed ID: 28194671
[TBL] [Abstract][Full Text] [Related]
11. Non-alcoholic fatty liver disease alters expression of genes governing hepatic nitrogen conversion.
Eriksen PL; Vilstrup H; Rigbolt K; Suppli MP; Sørensen M; Heebøll S; Veidal SS; Knop FK; Thomsen KL
Liver Int; 2019 Nov; 39(11):2094-2101. PubMed ID: 31386258
[TBL] [Abstract][Full Text] [Related]
12. CCL20 is up-regulated in non-alcoholic fatty liver disease fibrosis and is produced by hepatic stellate cells in response to fatty acid loading.
Chu X; Jin Q; Chen H; Wood GC; Petrick A; Strodel W; Gabrielsen J; Benotti P; Mirshahi T; Carey DJ; Still CD; DiStefano JK; Gerhard GS
J Transl Med; 2018 Apr; 16(1):108. PubMed ID: 29690903
[TBL] [Abstract][Full Text] [Related]
13. Sorafenib reduces steatosis-induced fibrogenesis in a human 3D co-culture model of non-alcoholic fatty liver disease.
Romualdo GR; Da Silva TC; de Albuquerque Landi MF; Morais JÁ; Barbisan LF; Vinken M; Oliveira CP; Cogliati B
Environ Toxicol; 2021 Feb; 36(2):168-176. PubMed ID: 32918399
[TBL] [Abstract][Full Text] [Related]
14. Investigating fibrosis and inflammation in an ex vivo NASH murine model.
Gore E; Bigaeva E; Oldenburger A; Jansen YJM; Schuppan D; Boersema M; Rippmann JF; Broermann A; Olinga P
Am J Physiol Gastrointest Liver Physiol; 2020 Feb; 318(2):G336-G351. PubMed ID: 31905025
[TBL] [Abstract][Full Text] [Related]
15. Cyclooxygenase-2 expression in hepatocytes attenuates non-alcoholic steatohepatitis and liver fibrosis in mice.
Motiño O; Agra N; Brea Contreras R; Domínguez-Moreno M; García-Monzón C; Vargas-Castrillón J; Carnovale CE; Boscá L; Casado M; Mayoral R; Valdecantos MP; Valverde ÁM; Francés DE; Martín-Sanz P
Biochim Biophys Acta; 2016 Sep; 1862(9):1710-23. PubMed ID: 27321932
[TBL] [Abstract][Full Text] [Related]
16. Expression of STING Is Increased in Liver Tissues From Patients With NAFLD and Promotes Macrophage-Mediated Hepatic Inflammation and Fibrosis in Mice.
Luo X; Li H; Ma L; Zhou J; Guo X; Woo SL; Pei Y; Knight LR; Deveau M; Chen Y; Qian X; Xiao X; Li Q; Chen X; Huo Y; McDaniel K; Francis H; Glaser S; Meng F; Alpini G; Wu C
Gastroenterology; 2018 Dec; 155(6):1971-1984.e4. PubMed ID: 30213555
[TBL] [Abstract][Full Text] [Related]
17. Hepatocyte nuclear receptor SHP suppresses inflammation and fibrosis in a mouse model of nonalcoholic steatohepatitis.
Zou A; Magee N; Deng F; Lehn S; Zhong C; Zhang Y
J Biol Chem; 2018 Jun; 293(22):8656-8671. PubMed ID: 29666185
[TBL] [Abstract][Full Text] [Related]
18. Nutrigenomics analysis reveals that copper deficiency and dietary sucrose up-regulate inflammation, fibrosis and lipogenic pathways in a mature rat model of nonalcoholic fatty liver disease.
Tallino S; Duffy M; Ralle M; Cortés MP; Latorre M; Burkhead JL
J Nutr Biochem; 2015 Oct; 26(10):996-1006. PubMed ID: 26033743
[TBL] [Abstract][Full Text] [Related]
19. Ipragliflozin, an SGLT2 inhibitor, exhibits a prophylactic effect on hepatic steatosis and fibrosis induced by choline-deficient l-amino acid-defined diet in rats.
Hayashizaki-Someya Y; Kurosaki E; Takasu T; Mitori H; Yamazaki S; Koide K; Takakura S
Eur J Pharmacol; 2015 May; 754():19-24. PubMed ID: 25701721
[TBL] [Abstract][Full Text] [Related]
20. CXC Motif Ligand 16 Promotes Nonalcoholic Fatty Liver Disease Progression via Hepatocyte-Stellate Cell Crosstalk.
Jiang L; Yang M; Li X; Wang Y; Zhou G; Zhao J
J Clin Endocrinol Metab; 2018 Nov; 103(11):3974-3985. PubMed ID: 30053055
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
